Skip to search formSkip to main contentSkip to account menu

Rifalazil

Known as: 3'-hydroxy-5'-(4-isobutyl-1-piperazinyl)benzoxazinorifamycin, 3'-hydroxy-5'-(4-isobutylpiperazinyl)benzoxazinorifamycin, benzoxazinorifamycin 
National Institutes of Health

Related topics

Related topics

1 relation

Narrower (1)

KRM 1648

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2010
Review
2010
Rifamycins--obstacles and opportunities.
Review
2010
Review
2010
Resistance to rifampicin: at the crossroads between ecological, genomic and medical concerns.
2008
2008
Bisphosphonated Benzoxazinorifamycin Prodrugs for the Prevention and Treatment of Osteomyelitis
Osteomyelitis represents a challenge to modern medicine. This inflammatory process is accompanied by bone necrosis, and results… 
Highly Cited
2007
Highly Cited
2007
In Vitro Activities of 15 Antimicrobial Agents against 110 Toxigenic Clostridium difficile Clinical Isolates Collected from 1983 to 2004
ABSTRACT The incidence and severity of Clostridium difficile-associated disease (CDAD) is increasing, and standard treatment is… 
Highly Cited
2004
Highly Cited
2004
Rifalazil Treats and Prevents Relapse of Clostridium difficile-Associated Diarrhea in Hamsters
ABSTRACT Although vancomycin and metronidazole effectively treat Clostridium difficile-associated diarrhea and colitis (CDAD… 
Highly Cited
2001
Highly Cited
2001
Safety and Bactericidal Activity of Rifalazil in Patients with Pulmonary Tuberculosis
ABSTRACT Rifalazil, also known as KRM-1648 or benzoxazinorifamycin, is a new semisynthetic rifamycin with a long half-life of… 
Highly Cited
1997
Highly Cited
1997
HIV protease inhibitors, saquinavir, indinavir and ritonavir: inhibition of CYP3A4-mediated metabolism of testosterone and benzoxazinorifamycin, KRM-1648, in human liver microsomes.
1995
1995
In vitro activity of the benzoxazinorifamycin KRM-1648 against drug-susceptible and multidrug-resistant tubercle bacilli
We investigated the activity of benzoxazinorifamycin (KRM-1648) against several drug-susceptible and multidrug-resistant strains… 
Highly Cited
1995
Highly Cited
1995
In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis
The in vitro and in vivo activities of a new benzoxazinorifamycin, KRM-1648 (KRM), against Mycobacterium tuberculosis were… 
Highly Cited
1992
Highly Cited
1992
Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex infection induced in mice
Newly synthesized benzoxazinorifamycin, KRM-1648, was studied for its in vivo anti-Mycobacterium avium complex (MAC) activities… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)